Catalyst MedTech, a leader in nuclear medicine and molecular imaging solutions, has announced it will serve as the exclusive U.S. distributor of CareMiBrain, an ultra-high resolution dedicated brain PET system developed by MindView / OncoVision.
Designed specifically for neurologic imaging and research, the companies say that CareMiBrain delivers ‘ultra-high’ resolution, ‘high’ sensitivity, and ‘superior’ patient comfort, in a compact footprint that integrates ‘seamlessly’ into imaging departments, outpatient centres, or as a standalone solution in private practices.
The companies say this system opens a new window into the human brain, advancing the ability to understand cognition, disease progression, and potential pathways to recovery. The complete solution will be publicly showcased for the first time in the U.S. in Catalyst MedTech’s Booth (#701) during the SNMMI 2025 Annual Meeting in New Orleans.
“This is more than a distribution agreement,” said Martin Shirley, President and CEO of Catalyst MedTech. “This is a defining moment. As part of Catalyst’s U.S. market strategy, we’ve paired CareMiBrain with Syntermed’s NeuroQ4, the industry’s leading brain analysis software. NeuroQ4 provides advanced analysis for neurologic PET images for Epilepsy, Oncology and Amyloid Analysis (including centiloids). Catalyst MedTech is delivering the complete neurologic PET solution U.S. physicians have been waiting for. As an extension of our company’s purpose, our legacy will now include this complete Neurologic PET solution.”
Developed by OncoVision MindView, CareMiBrain features a detector technology platform—continuous monolithic crystal, SiPM arrays, custom electronics, and proprietary software—designed to optimise clarity, quantification, and patient compliance.
“We’re not here just to serve our purpose, we’re here to move the field forward,” added Shirley. “Catalyst exists to deliver value and access to advanced diagnostic imaging and therapeutic innovation. That’s who we are. That’s what we do. We are nuclear medicine and molecular imaging.”
